"This study aimed to identify bioimaging biomarkers that could possibly correlate with amyloid patients. If a careful medical history is taken from the patient, the right multimodal imaging is ...
Stand Up To Cancer ® (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, ...
This transcript has been edited for clarity. Gayatri Acharya, MD: Greetings. I'm Dr Gayatri Acharya, cardiology fellow at Mayo Clinic. During today's roundtable, we'll be discussing cardiac ...
Owing to the low incidence of AL amyloidosis, large studies are scarce and hardly any randomized, controlled studies comparing different therapeutic regimens have been conducted. Comparison of studies ...
Although it is rare, cardiac amyloidosis is an important heart disease to pay attention to because its symptoms can be easy to overlook and often resemble those of other heart ...
AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain (AL) amyloidosis in two Phase III trials. A light chain depleter antibody, anselamimab was being investigated in ...
LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (IMMX) (“ImmixBio”, “Company”, “We” or “Us” or "IMMX”), a clinical-stage ...
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II) For over half a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results